Concord Drugs Q1 Results
- BSE: 538965
- NSE: -
- ISIN: INE858L01010
- Sector: Biotechnology & Drugs
BSE
75.00
1.98 (2.71%)
1.98 (2.71%)Volume433.00
Updated: Fri 6 Mar, 2026 | 15:24:32
NSE
This stock is not traded on NSE
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q1 Results Highlights
Quarter ended Jun 25
Note: Comparison is on QoQ basis
Quarterly - Concord Drugs Q1 Results
*All figures in crores except per share values
| Fiscal Period | Jun 25 | Mar 25 | QoQ Comp | Jun 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 12.96 | 9.73 | 33.21% | 11.20 | 15.71% |
| Depreciation/ Amortization | 0.37 | 0.38 | -2.62% | 0.34 | 8.62% |
| Operating Income | 0.65 | 0.66 | -2.39% | 0.49 | 31.31% |
| Net Income | 0.12 | 0.04 | 202.31% | 0.03 | 332.35% |
| Other Operating Expenses Total | 0.29 | 0.21 | 39.23% | 0.38 | -25.03% |
| Net Income Before Taxes | 0.16 | 0.06 | 172.93% | 0.04 | 287.99% |
| Total Revenue | 13.61 | 10.39 | 30.94% | 11.69 | 16.36% |
| Selling/ General/ Admin Expenses Total | 0.89 | 1.24 | -28.45% | 1.46 | -39.24% |
| Diluted Normalized EPS | 0.12 | 0.04 | 216.79% | 0.03 | 298.54% |